Abstracts tagged "treatment"

Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
K. L. Winthrop¹, H. Valdez², E. Mortensen³, R. Chew⁴, S. Krishnaswami⁵, T. Kawabata⁵ and R. Riese⁴, ¹Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ²Pfizer Inc., New York, NY, ³Global Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…
Abstract Number: 1318 • 2012 ACR/ARHP Annual Meeting
Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Vibeke Strand¹, Oana Purcaru², Ronald F. van Vollenhoven³, Ernest Choy⁴ and Roy Fleischmann⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ²UCB Pharma, Brussels, Belgium, ³Karolinska Institute, Stockholm, Sweden, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵Southwestern Medical Center at Dallas, University of Texas, Dallas, TX
Background/Purpose: Certolizumab pegol (CZP) monotherapy administered every 4 weeks (Q4W) for rheumatoid arthritis (RA) has been shown to be associated with rapid and sustainable improvements…
Abstract Number: 997 • 2012 ACR/ARHP Annual Meeting
Evidence of Novel Genetic Predictors of Methotrexate Efficacy in Rheumatoid Arthritis
Stella Aslibekyan¹, Maria I. Danila², Jin Sha¹, David T. Redden³, Richard J. Reynolds⁴, Elizabeth Brown⁵, Laura B. Hughes⁶, Molly S. Bray¹, Sarah L. Morgan⁷, Larry W. Moreland⁸, James R. O'Dell⁹, Jeffrey R. Curtis¹⁰, Robert P. Kimberly¹¹, Lindsey A. Criswell¹², Robert M. Plenge¹³, S. Louis Bridges Jr.¹⁴ and Donna K. Arnett¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Med/Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ³Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, ⁶Med Div of Clin Imm & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama Birmingham, Birmingham, AL, ⁸Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ¹⁰Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ¹¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹²Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹³Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX), a disease-modifying anti-rheumatic drug used as first-line therapy in rheumatoid arthritis (RA), is characterized by considerable heterogeneity in individual treatment response. We…
Abstract Number: 375 • 2012 ACR/ARHP Annual Meeting
Cell Phone Based Automated Monitoring of Patients with Early Rheumatoid Arthritis
Kari Puolakka¹, Tuulikki Sokka² and Hannu Kautiainen³, ¹Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ²Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ³Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland
Cell phone based automated monitoring of patients with early rheumatoid arthritis Background/Purpose: Frequent monitoring improves patient compliance and outcomes of RA. Limited resources may hinder adherence…
Abstract Number: 2481 • 2012 ACR/ARHP Annual Meeting
Time Trends in Corticosteroid Use in Rheumatoid Arthritis: Results From a Population Based Inception Cohort 1980–1994 Vs. 1995–2007
Ashima Makol¹, John M. Davis III², Cynthia S. Crowson³, Terry M. Therneau³, Sherine E. Gabriel⁴ and Eric L. Matteson², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Corticosteroids (CS) are a double edged sword in rheumatoid arthritis (RA) treatment. Low doses may have disease modifying effects but long-term use risks detrimental…
Abstract Number: 1319 • 2012 ACR/ARHP Annual Meeting
Certolizumab Pegol Plus Methotrexate Is Similarly Effective in Active Rheumatoid Arthritis Secondary Non-Responders to Anti-TNF Inhibitors: Post-Hoc Analysis of a Phase Iiib Trial
Daniel Furst¹, Saeed A. Shaikh², Maria W. Greenwald³, Michael H. Schiff⁴, Barbara Bennett⁵, Owen Davies⁶, Fabienne Staelens⁷, Will Koetse⁸ and Philippe Bertin⁹, ¹David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ²Medicine, McMaster University, St Catharines, ON, Canada, ³Desert Medical Advances, Palm Desert, CA, ⁴Rheumatology Division, University of Colorado, Denver, CO, ⁵BABennett Consulting, LLC, Marietta, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Rtp, NC, ⁹Service De Rhumatologie, Dupuytren Hospital, Limoges, France
Background/Purpose: Certolizumab pegol (CZP) has demonstrated efficacy in patients (pts) with prior TNF inhibitor exposure.1 In the Doseflex trial two maintenance dosing regimens of CZP…
Abstract Number: 928 • 2012 ACR/ARHP Annual Meeting
Is There an Optimal Treatment Strategy for Disease-Modifying-Antirheumatic-Drug Naïve Patients with Rheumatoid Arthritis?
Roopa Akkineni¹ and Daniel A. Albert², ¹Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Medicine/Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: There is a lack of head-to-head clinical trial data to determine the most effective treatment for rheumatoid arthritis (RA). However, these trials have had…
Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Vernon F. Schabert¹, Crystal Watson², George Joseph², Paige Iversen¹, Chakkarin Burudpakdee¹ and David J. Harrison², ¹IMS Health, Alexandria, VA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…
Abstract Number: 2430 • 2012 ACR/ARHP Annual Meeting
Using the Internet in Help-Seeking As Illness Develops in Early Rheumatoid Arthritis
Anne F. Townsend¹, Jenny Leese¹, Catherine L. Backman², Paul M. Adam³ and Linda C. Li⁴, ¹Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, ³Rheumatology Liaison, Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁴Physical Therapy, Arthritis Centre of Canada, Richmond, BC, Canada
Background/Purpose: Patients’ Internet use for health purposes is regarded as potentially transformational. Using on-line resources is associated with the emergence of the e-patient; broadly defined…
Abstract Number: 1322 • 2012 ACR/ARHP Annual Meeting
Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis
Tong Zhu¹, Kazuo Oda², Udaya Valluri¹, Bogie Moore¹, Ying Cao¹, Vishala Chindalore³ and Bola Akinlade⁴, ¹Astellas Pharma Global Development, Inc., Northbrook, IL, ²Drug Metabolism Research Labs. Drug Discovery Research, Astellas Pharma Inc., Osaka, Japan, ³Pinnacle Research Group/Anniston Medical Clinic, Anniston, AL, ⁴Immunology Development, Astellas Pharma Global Development, Inc., Northbrook, IL
Background/Purpose: ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid arthritis (RA) and other autoimmune diseases.…
Abstract Number: 836 • 2012 ACR/ARHP Annual Meeting
Clinical Responses and Patient Reported Outcomes to NNC0109-0012 (anti-IL-20 mAb) in Rheumatoid Arthritis (RA) Patients Following 12-Weeks Dosing and 13 Weeks Follow up: Results From a Phase 2a Trial
Ladislav ŠEnolt¹, Marie Göthberg², Xavier Valencia³ and Eva Dokoupilova⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Biostatistics, Novo Nordisk, A/S, Soeborg, Denmark, ³Clinical Medical and Regulatory Affairs, Novo Nordisk, Inc., Princeton, NJ, ⁴Medical Plus s.r.o, Uherske Hradiste, Czech Republic
Background/Purpose: NNC0109-0012 (anti-IL-20 mAb) is a novel human monoclonal IgG4 antibody which binds to and neutralizes the activity of IL-20. Data from a phase 1…
Abstract Number: 359 • 2012 ACR/ARHP Annual Meeting
Improved Radiological Outcome of Rheumatoid Arthritis: Early Treatment with methotrexate might be a key Prognostic Factor
Christoph Fiehn¹, Elisabeth Belke-Voss¹, Dietmar Krause², Siegfried Wassenberg³ and Rolf Rau⁴, ¹ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ²Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany, ³Rheumaklinik, Evangelisches Fachkrankenhaus Ratingen, Rheumazentrum, Ratingen, Germany, ⁴Düsseldorf, Germany
Background/Purpose: To compare the rate of radiological progression in patients with rheumatoid arthritis (RA) diagnosed in the 1980s with those of the late 1990s until…
Abstract Number: 2327 • 2012 ACR/ARHP Annual Meeting
CGEN-15001, a Novel Negative Costimulatory Fusion Protein Is Effective in the Collagen-Induced Arthritis Mouse Model of Rheumatoid Arthritis
Iris Hecht¹, Kay McNamee², Ilan Vaknin³, Anat Oren³, Joseph R. Podojil⁴, Galit Rotman³, Eyal Neria³, Stephen D. Miller⁴ and Richard O. Williams², ¹R&D, Compugen Ltd., Tel Aviv, Israel, ²Kennedy Institute of Rheumatology, Oxford University, Oxford, United Kingdom, ³Compugen Ltd., Tel Aviv, Israel, ⁴Microbiology-Immunology, Northwestern University, Chicago, IL
Background/Purpose: CGEN-15001 is a recombinant Fc fusion protein consisting of the extracellular domain of CGEN-15001T, a protein predicted to be a member of the B7/CD28…
Abstract Number: 1297 • 2012 ACR/ARHP Annual Meeting
Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis — Lack of Improvement in Disease Activity Score by 3 Months Predicts Low Likelihood of Low Disease Activity At 1 Year
Ronald F. van Vollenhoven¹, Sriram Krishnaswami², Birgitta Benda³, David Gruben⁴, Bethanie Wilkinson⁴, Charles A. Mebus⁴, Samuel H. Zwillich² and John Bradley², ¹Karolinska Institute, Stockholm, Sweden, ²Pfizer Inc, Groton, CT, ³Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This post-hoc analysis of the…
Abstract Number: 831 • 2012 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab (AMG 827) in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Karel Pavelka¹, Yun Chon², Richard Newmark², Ngozi Erondu³ and Shao- Lee Lin², ¹Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty, Charles University Prague, Prague, Czech Republic, ²Clinical Development, Amgen Inc, Thousand Oaks, CA, ³Amgen Inc, Thousand Oaks, CA
Background/Purpose: A potential role for IL-17 in rheumatoid arthritis (RA) has been supported by data from clinical studies of inhibitors of the IL-17A ligand. To…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].